Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (NASDAQ: OM) has secured a national contract with the United States Department of Veterans Affairs to enhance the availability of its Tablo® Hemodialysis System in 106 VA hospitals across the U.S. This five-year contract allows for indefinite quantities of Tablo units to provide advanced dialysis care, benefiting 35,000 veterans. The Tablo system, FDA-cleared, supports at-home and acute care, featuring two-way cloud communication for patient monitoring, thus transforming the dialysis experience.
Outset Medical, Inc. (Nasdaq: OM) announces FDA clearance for the Tablo® Hemodialysis System and resumes shipments for home use, reflecting a commitment to patient autonomy in dialysis.
For Q2 2022, revenue reached $25.1 million, matching prior guidance, with gross margin improving to 15.1% compared to 4.2% in Q2 2021. However, operating expenses rose to $47.5 million, contributing to a net loss of ($43.8) million.
Full-year guidance projects revenue between $105 million and $110 million, indicating modest growth over 2021.
Outset Medical, Inc. (NASDAQ: OM) announced a shipment hold on its Tablo Hemodialysis System for home use, pending FDA review of a 510(k) submission for updates since its original March 2020 clearance. The company reports no safety issues with Tablo and will continue marketing it for healthcare professionals. Revised revenue expectations for the second quarter of 2022 are now at least
Outset Medical, Inc. (Nasdaq: OM) has announced management participation in two investor conferences. The UBS Global Healthcare Conference will take place on May 24, 2022, at 4:45am PT, while the Goldman Sachs 43rd Annual Global Healthcare Conference is set for June 14, 2022, at 3:20pm PT. A live and archived webcast of these fireside chats will be available on Outset's investor website. Outset continues to innovate with its Tablo Hemodialysis System, designed to enhance dialysis care accessibility and efficiency.
Outset Medical, Inc. (Nasdaq: OM) announces a virtual webinar on the Tablo® Hemodialysis System for home dialysis, taking place on June 1, 2022, at 1:00 PM PT / 4:00 PM ET. The event features discussions between patients and nephrologists, moderated by Michael Aragon, MD. It aims to share patient experiences and the journey of home dialysis. Attendees can register here. An archived version will be available on Outset's website.
Outset Medical reported a remarkable 33.3% revenue growth in Q1 2022, reaching $30.6 million compared to $22.9 million in Q1 2021. Gross margin improved significantly to 14.5%, up from 1.3% the previous year. The company achieved a product revenue increase of 40.9% to $25.7 million. Despite these positive metrics, the net loss grew to $36.9 million or ($0.78) per share. Full-year revenue guidance now ranges from $144 million to $150 million, suggesting continued strong growth momentum.
Outset Medical, Inc. (Nasdaq: OM) will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:00 PM PT / 3:00 PM ET. This event will showcase their innovative Tablo Hemodialysis System, designed to reduce costs and complexities in dialysis treatment. An archived webcast will be available on the company’s website. The Tablo system represents a significant advancement in dialysis care, enabling treatment anywhere and anytime, enhancing patient experience and provider efficiency.
Outset Medical, Inc. (NASDAQ: OM) has appointed Dale E. Jones to its Board of Directors, effective immediately. With over 30 years of experience in team building and human capital issues, Jones aims to contribute to Outset's growth in the medical technology sector. His previous roles include Senior Advisor at Diversified Search Group and CEO for over eight years. Outset's flagship product, the Tablo Hemodialysis System, simplifies dialysis for patients and providers, highlighting the company's commitment to innovation in healthcare.
Outset Medical, Inc. (NASDAQ: OM) will release its first quarter 2022 financial results on May 4, 2022, after market close. A conference call, led by CEO Leslie Trigg and CFO Nabeel Ahmed, is scheduled for 2:00 PM PT (5:00 PM ET) on the same day to discuss these results. The company specializes in innovative dialysis solutions, particularly the FDA-cleared Tablo® Hemodialysis System, which simplifies dialysis processes and improves patient care.
Outset Medical, Inc. (NASDAQ: OM) reported new data on its Tablo Hemodialysis System at the 2022 NKF Spring Clinical Meetings in Boston. A national survey showed that 72% of dialysis patients believe Tablo offers significant clinical improvements, while 77% would consider home hemodialysis. Additionally, 77% of nephrologists view Tablo as superior to existing devices, with 98% inclined to recommend it to patients. The costs associated with peritoneal dialysis (PD) failure can exceed $72,000 per patient in hospitalization, highlighting the potential cost benefits of transitioning to home hemodialysis sooner.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
